Novartis AG
NOVN,
NVS,
said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary endpoints.
The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia who would normally undergo blood transfusions, according to the company.
“Iptacopan was well tolerated with a favorable safety profile consistent with previously reported data,” Novartis said.
Write to Cecilia Butini at [email protected]
